Each year 31 million people are afflicted with chronic sinusitis, making it one of the most common health conditions in the United States. The sinuses are air-filled cavities located within the bones around the nose and eyes that allow for natural ventilation and drainage. In Chronic Sinusitis, the sinus linings become inflamed, blocking the natural drainage passageways and leading to chronic infections and nasal obstruction.
Patients with chronic sinusitis often suffer from debilitating symptoms such as facial pain or pressure, nasal congestion and difficulty breathing, discolored nasal discharge, loss of smell and taste, headache, fatigue and depression.
Propel Steroid Releasing Implant
Intersect ENT has developed the PROPEL dissolvable implant for patients with chronic sinusitis that necessitate a sinus surgery. This is the first and only sinus surgery product that is backed by Level 1-A evidence. PROPEL offers localized & controlled drug delivery directly to the sinus tissue. The product is inserted by our physicians to maintain the surgical opening, the spring-like implant expands to prop open the ethmoid sinus and gradually delivers an advanced corticosteroid (mometasone furoate) with anti-inflammatory properties directly to the sinus lining as the implant dissolves.
The PROPEL system has been clinically proven to prevent obstruction of the ethmoid sinus following surgery. The results demonstrated improved post-operative outcomes and reduced the need for additional surgical procedures such as adhesion lysis and systemic steroids.